{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:11:03Z","timestamp":1787019063046,"version":"build-2736575974"},"reference-count":45,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T00:00:00Z","timestamp":1662422400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Open Access funding provided by the Qatar National Library."}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Cancer Control"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:p>Coronavirus disease 2019 (COVID-19) infection is caused by severe acute respiratory syndrome coronavirus 2. Adults with cancer are immunocompromised due to several causes including cancer itself and immunosuppressive therapy. Thus, cancer patients are more susceptible to develop COVID-19 infection. As COVID-19 vaccines became available, patients with cancer would benefit from receiving the vaccine. This article aims to review the recent evidences and recommendations about COVID-19 vaccination in cancer patients.<\/jats:p>\n                  <jats:p>Current guidelines recommend that patients with cancer should have the priority to receive the vaccine given their immunocompromised state. The timing of administration varies depending on cancer type and treatment. Generally, the vaccine should be given before starting the chemotherapy if possible or in between chemotherapy cycles and away from nadir phase. For other cancer treatments, it is recommended to give the vaccine when there is evidence of blood count recovery. In general, induction therapy and treatment for newly diagnosed patients should not be delayed for the vaccination purpose. It is noteworthy to mention that cancer patients especially those with hematologic malignancies might have absented or attenuated response to the vaccine due to their pathophysiological status.<\/jats:p>\n                  <jats:p>On the other hand, the current vaccine guidelines have been criticized for lacking evidence on some important topics that need to be addressed. Firstly, some vaccines have been granted an emergency use authorization, prior to the usual comprehensive safety and efficacy evaluation process. Secondly, specific populations including cancer patients were excluded from the approval trials for safety reasons. Finally, some recommendations regarding the COVID-19 vaccines are extrapolated from other vaccines studies. Further studies are required to fill these gaps and observational studies that include cancer patients are warranted to have a better understanding of the safety and efficacy of the vaccines in cancer patients.<\/jats:p>","DOI":"10.1177\/10732748221106266","type":"journal-article","created":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T07:18:40Z","timestamp":1662448720000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":10,"title":["COVID-19 Vaccination in Cancer Patients: A Review Article"],"prefix":"10.1177","volume":"29","author":[{"given":"Rana","family":"Mekkawi","sequence":"first","affiliation":[{"name":"Independent researcher"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bassant A.","family":"Elkattan","sequence":"additional","affiliation":[{"name":"Independent researcher"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaaeldin","family":"Shablak","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8625-6178","authenticated-orcid":false,"given":"Mohammad","family":"Bakr","sequence":"additional","affiliation":[{"name":"Department of Clinical Hematology, National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1144-8076","authenticated-orcid":false,"given":"Mohamed A.","family":"Yassin","sequence":"additional","affiliation":[{"name":"Department of Clinical Hematology, National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8291-7987","authenticated-orcid":false,"given":"Nabil E.","family":"Omar","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2022,9,6]]},"reference":[{"key":"bibr1-10732748221106266","unstructured":"Coronavirus disease (COVID-19) \u2013 World health organization. Who.int. 2021. https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019?gclid=EAIaIQobChMIutavzHm7AIVFHZgCh0VNQbnEAAYASAAEgKPCPD_BwE. Accessed October 1, 2021."},{"key":"bibr2-10732748221106266","volume-title":"Coronavirus Disease 2019 (COVID-19)","year":"2021"},{"key":"bibr3-10732748221106266","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00858"},{"key":"bibr4-10732748221106266","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.1218"},{"key":"bibr5-10732748221106266","unstructured":"Why people with cancer are more likely to get infections. Cancer.org. 2021. https:\/\/www.cancer.org\/treatment\/treatments-and-side-effects\/physical-side-effects\/low-blood-counts\/infections\/why-people-with-cancer-are-at-risk.html. Accessed October 1, 2021."},{"key":"bibr6-10732748221106266","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit684"},{"key":"bibr7-10732748221106266","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2015.1062189"},{"key":"bibr8-10732748221106266","unstructured":"Emergency use authorization for vaccines explained. Silver Spring, MD: U.S. Food and Drug Administration. 2021. https:\/\/www.fda.gov\/vaccines-blood-biologics\/vaccines\/emergency-use-authorization-vaccines-explained. Accessed October 1, 2021."},{"key":"bibr10-10732748221106266","unstructured":"Pfizer and BioNTech conclude phase 3 study of COVID-19 vaccine candidate, meeting all primary efficacy endpoints. Pfizer.com. 2021. https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer-and-biontech-conclude-phase-3-study-covid-19-vaccine. Accessed October 1, 2021."},{"key":"bibr11-10732748221106266","unstructured":"U.S. Food and Drug Administration. Coronavirus (COVID-19) update: FDA authorizes pfizer-BioNTech COVID-19 vaccine for emergency use in adolescents in another important action in fight against pandemic. 2022. https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-authorizes-pfizer-biontech-covid-19-vaccine-emergency-use. Accessed 20 January 2022."},{"key":"bibr12-10732748221106266","unstructured":"U.S. Food and Drug Administration. FDA authorizes Pfizer-BioNTech COVID-19 vaccine for emergency use in children 5 through 11 years of age. 2022. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-authorizes-pfizer-biontech-covid-19-vaccine-emergency-use-children-5-through-11-years-age. Accessed 20 January 2022."},{"key":"bibr13-10732748221106266","unstructured":"Moderna\u2019s COVID-19 vaccine candidate meets its primary efficacy endpoint in the first interim analysis of the phase 3 COVE study. Moderna, Inc. 2021. https:\/\/investors.modernatx.com\/news-releases\/news-release-details\/modernas-covid-19-vaccine-candidate-meets-its-primary-efficacy. Accessed October 1, 2021."},{"key":"bibr14-10732748221106266","unstructured":"COVID-19 subcommittee of the WHO global advisory committee on vaccine safety (GACVS): Updated statement regarding myocarditis and pericarditis reported with COVID-19 mRNA vaccines. Who.int. 2021. https:\/\/www.who.int\/news\/item\/27-10-2021-gacvs-statement-myocarditis-pericarditis-covid-19-mrna-vaccines-updated. Accessed December 9, 2021."},{"key":"bibr15-10732748221106266","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32661-1"},{"key":"bibr16-10732748221106266","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2107809"},{"key":"bibr17-10732748221106266","unstructured":"COVID-19 vaccination. Atlanta, GA: Centers for Disease Control and Prevention. 2021. https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/vaccines\/safety\/adverse-events.html. Accessed October 1, 2021."},{"key":"bibr18-10732748221106266","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30831-8"},{"key":"bibr19-10732748221106266","doi-asserted-by":"publisher","DOI":"10.2139\/ssrn.3822780"},{"key":"bibr20-10732748221106266","volume-title":"Novavax and serum institute of India receive emergency use authorization for COVID-19 vaccine in India","author":"Novavax Investor Relations","year":"2022"},{"key":"bibr21-10732748221106266","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107659"},{"key":"bibr22-10732748221106266","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116185"},{"key":"bibr24-10732748221106266","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-1817"},{"key":"bibr25-10732748221106266","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2021.12.062"},{"key":"bibr26-10732748221106266","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm695152e2"},{"key":"bibr27-10732748221106266","unstructured":"COVID-19 vaccines & patients with cancer. Alexandria, VA: ASCO. 2021. https:\/\/www.asco.org\/covid-resources\/vaccines-patients-cancer. Accessed October 1, 2021."},{"key":"bibr28-10732748221106266","unstructured":"ASH-ASTCT COVID-19 and vaccines: Frequently asked questions. Hematology.org. 2021. https:\/\/www.hematology.org\/covid-19\/ash-astct-covid-19-and-vaccines. Accessed October 1, 2021."},{"key":"bibr29-10732748221106266","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2021.06.014"},{"key":"bibr30-10732748221106266","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021011568"},{"key":"bibr31-10732748221106266","volume-title":"MSK COVID-19 Vaccine Interim Guidelines For Cancer Patients","author":"Memorial Sloan Kettering Cancer Center","year":"2021"},{"key":"bibr32-10732748221106266","unstructured":"ASH-ASTCT COVID-19 vaccination for HCT and CAR T cell recipients. Hematology.org. 2021. https:\/\/www.hematology.org\/covid-19\/ash-astct-covid-19-vaccination-for-hct-and-car-t-cell-recipients. Accessed October 1, 2021."},{"key":"bibr33-10732748221106266","unstructured":"COVID-19 vaccines. Version 7. EBMT. 2021. https:\/\/www.ebmt.org\/sites\/default\/files\/2021-10\/COVID-vaccines-version-7.22-2021-10-03.pdf. Accessed October 1, 2021."},{"key":"bibr34-10732748221106266","unstructured":"NCCN. Recommendations of the national comprehensive cancer network\u00ae (NCCN\u00ae) COVID-19 vaccination advisory committee*. 2021. https:\/\/www.nccn.org\/docs\/default-source\/covid-19\/2021_covid-19_vaccination_guidance_v4-0.pdf?sfvrsn=b483da2b_70"},{"key":"bibr35-10732748221106266","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2021.03.876"},{"key":"bibr36-10732748221106266","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01046-w"},{"key":"bibr37-10732748221106266","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.19.00495"},{"key":"bibr38-10732748221106266","unstructured":"Clinician frequently asked questions (FAQs) and guidance on COVID19 vaccine for patients receiving systemic anti-cancer therapy. 2021. https:\/\/b-s-h.org.uk\/media\/19241\/clinician-faqs-and-guidance-on-covid19-vaccine-for-patients-receiving-sa_.pdf. Accessed October 1, 2021."},{"key":"bibr39-10732748221106266","unstructured":"ASTRO recommendation on COVID-19 vaccination for patients receiving radiation therapy - The ASCO post. Ascopost.com. 2021. https:\/\/ascopost.com\/issues\/march-25-2021\/astro-recommendation-on-covid-19-vaccination-for-patients-receiving-radiation-therapy\/. Accessed October 1, 2021."},{"key":"bibr40-10732748221106266","unstructured":"Interim clinical considerations for use of COVID-19 vaccines. Cdc.gov. 2021. https:\/\/www.cdc.gov\/vaccines\/covid-19\/clinical-considerations\/covid-19-vaccines-us.html. Accessed October 1, 2021."},{"key":"bibr41-10732748221106266","unstructured":"Safety of COVID-19 vaccines. Atlanta, GA: Centers for Disease Control and Prevention. 2021. https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/vaccines\/safety\/safety-of-vaccines.html. Accessed October 1, 2021."},{"key":"bibr42-10732748221106266","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00155-8"},{"key":"bibr43-10732748221106266","volume-title":"SBI Recommendations for the Management of Axillary Adenopathy in Patients with Recent COVID-19 Vaccination","year":"2021"},{"key":"bibr44-10732748221106266","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.1967"},{"key":"bibr45-10732748221106266","unstructured":"Include cancer patients in COVID-19 vaccine trials, say ASCO and friends of cancer research. Rockville, MD: Regulatory Affairs Professionals Society. 2021. https:\/\/www.raps.org\/news-and-articles\/news-articles\/2021\/6\/include-cancer-patients-in-covid-19-vaccine-trials. Accessed October 1, 2021."},{"key":"bibr46-10732748221106266","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-020-00122-3"},{"key":"bibr47-10732748221106266","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.01.046"}],"container-title":["Cancer Control"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10732748221106266","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10732748221106266","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10732748221106266","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:22:42Z","timestamp":1777386162000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10732748221106266"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,6]]},"references-count":45,"alternative-id":["10.1177\/10732748221106266"],"URL":"https:\/\/doi.org\/10.1177\/10732748221106266","relation":{},"ISSN":["1073-2748","1526-2359"],"issn-type":[{"value":"1073-2748","type":"print"},{"value":"1526-2359","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,6]]},"article-number":"10732748221106266"}}